Suchergebnisse - "Hardtke, Svenja"

PubPharm (70)

1

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

enthalten in: NPJ vaccines | 2024

von Mayer, L. | Weskamm, L. | Fathi, A. | +15

2

Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2024

von Anastasiou, O. | Caruntu, F. | Curescu, M. | +21

3

Five‐year follow‐up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

enthalten in: Liver International | 2024

von Anastasiou, O. | Caruntu, F. | Curescu, M. | +21

4

Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients

enthalten in: Hepatology (Baltimore, Md.) | 2023

von Gömer, A. | Klöhn, M. | Jagst, M. | +11

5

Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D : An analysis of the HIDIT-II trial

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2023

von Dinkelborg, K. | Kahlhöfer, J. | Dörge, P. | +29

6

Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D : An analysis of the HIDIT‐II trial

enthalten in: Liver International | 2023

von Dinkelborg, K. | Kahlhöfer, J. | Dörge, P. | +28

7

Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C

enthalten in: The Journal of infectious diseases | 2022

von Khera, T. | Du, Y. | Todt, D. | +12

8

Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatment

enthalten in: European journal of immunology | 2022

von Du, Y. | Khera, T. | Strunz, B. | +13

9

HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta

enthalten in: Hepatology communications | 2022

von Sandmann, L. | Yurdaydin, C. | Deterding, K. | +9

10

MSarsCoV2 - Entwicklung eines rekombinanten viralen Vektorimpfstoffes zur aktiven Immunisierung von Risikogruppen gegen klinische SARS-2 Coronavirus Infektionen : Schlussbericht Förderkennzeichen: 01KI20702 : Laufzeit: 20.02.2020-31.12.2021

Erschienen: Dessau-Rosslau, IDT Biologika GmbH, 30.06.2022

von Kardinahl, S. | Ackenhausen, D. | Hesterkamp, T. | +1

1
2
3
4
5
6
7
Nächster »
[7]